Navigation Links
Favrille Announces Data From Phase 2 Clinical Trial of FavId for,Indolent B-Cell Non-Hodgkin's Lymphoma in Europe

Data Reported at the Congress of the European Hematology Association

SAN DIEGO, June 11, 2007 /PRNewswire-FirstCall/ -- Favrille, Inc. , a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced interim data from a Phase 2 clinical trial of FavId(R) in patients with indolent B-cell non-Hodgkin's lymphoma (NHL). The data were reported at the Congress of the European Hematology Association in Vienna on Saturday.

"We are encouraged by the preliminary results from this trial, which included patients with differing forms of indolent B-cell NHL," said Emanuele Zucca, M.D., co-investigator and Head of the Lymphoma Unit at the Oncology Institute of Southern Switzerland. "We are also encouraged by the feasibility of administering a patient-specific active immunotherapy, manufactured in the U.S., in patients in Europe."

A copy of Dr. Zucca's presentation is now available on Favrille's website at http://www.favrille.com.

This ongoing Phase 2 clinical trial is open to patients with various indolent forms of B-cell NHL who are either treatment-naïve, relapsed or refractory following prior chemotherapy, or relapsed following a prior response to Rituxan. The trial is expected to enroll 15 patients, but enrollment may be expanded if activity is seen in any specific patient subset.

About FavId

FavId is a patient-specific, Id/KLH active immunotherapy for the treatment of B-cell NHL. Favrille completed enrollment in its pivotal Phase 3 clinical trial of FavId following Rituxan induction therapy in patients with follicular B-cell NHL in January 2006. The trigger for the analysis of the primary endpoint in the trial, time to tumor progression (TTP), is based on a specific number of patients reaching disease progression. This is currently projected to occur around the en
'"/>




Page: 1 2 3

Related medicine technology :

1. Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:3/2/2015)... , March 2, 2015   Polymedco is committed to ...  During CRC Awareness Month, we are offering all existing ... , Posters – to be hung in ... CRC Patient Brochures with Stand – to be placed ... – to be put on/in patient charts as a ...
(Date:3/2/2015)... HACKENSACK, N.J. , March 2, 2015  Champions ... development of advanced technology solutions and services to personalize ... a 30 day extension on the $2 million convertible ... on December 1, 2014.  Dr. ... remarked, "Champions continues to benefit from the confidence and ...
(Date:3/2/2015)... 2, 2015  Kush Bottles, North ... solutions for the marijuana industry, announced today that ... been nominated for a 2015 Excellence in Entrepreneurship ... Award is designed to recognize individuals who exemplify ... their creativity and determination, have established and nurtured ...
Breaking Medicine Technology:Polymedco CDP, LLC. Promotes March as Colorectal Cancer Awareness Month 2Champions Oncology Extends Convertible Debt Financing 2Champions Oncology Extends Convertible Debt Financing 3Kush Bottles CEO, Nicholas Kovacevich, Nominated for 2015 "Excellence in Entrepreneurship Award" 2
... Market Publishers Ltd and GenericsWeb Pty Ltd signed partnership ... is now authorized to distribute and sell GenericsWeb ... Head of Partner Relations Department, mentioned in her comments ... whose title speaks for itself – the company focuses ...
... 2010 DURECT Corporation (Nasdaq: DRRX ) today ... and Pain Therapeutics, Inc. (Nasdaq: PTIE ) have ... for REMOXY® to the U.S. Food and Drug Administration (FDA) ... Therapeutics in December 2008.  This is a Class 2 resubmission ...
Cached Medicine Technology:Market Publishers Ltd and GenericsWeb Sign Partnership Agreement 2Market Publishers Ltd and GenericsWeb Sign Partnership Agreement 3REMOXY® New Drug Application Resubmitted 2REMOXY® New Drug Application Resubmitted 3
(Date:3/2/2015)... 02, 2015 A cocaine snorting ... from the typical nip slip or scathing scuffle. A ... is dawning the streets of Hollywood as Paper Jesus’ ... drug addiction and substance abuse in Hollywood. The Oscar ... take a political stance on the travails of drug ...
(Date:3/2/2015)... Angeles, CA (PRWEB) March 02, 2015 ... Buffett tickets at the Hollywood Bowl . This popular ... add customer appreciation promo code JIMMY-BUFFETT-2015 for added savings. ... because their favorite performer will be headlining at the ... This concert will be on Thursday, October 22nd and ...
(Date:3/2/2015)... 02, 2015 “ Wants and Needs ... monthly AppWatch, which features the latest and coolest mobile ... Tropeano, a mobile technology expert and host of NewsWatch, ... this app helps people evaluate priorities. , Whether a ... Wants and Needs app. The app allows people to ...
(Date:3/2/2015)... 02, 2015 Tyrone Christopher, Co-founder of ... medium for the model agency industry, have launched Softcandy.sexy, ... Mango, Passion Fruit, Pink Grapefruit, Pomegranate, and or Vanilla ... 1pm. , At a cost of alienating a few ... fire by announcing the brands commitment and support of ...
(Date:3/2/2015)... 02, 2015 ZoomCare announced today ... American healthcare. Zoom will expand its Portland on-demand ... and advanced care studios delivering urgent care, primary ... specialty care and outpatient surgery. With its new ... almost all healthcare needs outside of hospitalization. , ...
Breaking Medicine News(10 mins):Health News:Oscar Statue Snorting Cocaine Catches All Eyes in Hollywood, Ca 2Health News:Oscar Statue Snorting Cocaine Catches All Eyes in Hollywood, Ca 3Health News:Cheap Jimmy Buffett Tickets Hollywood Bowl: Ticket Down Slashes Prices on Jimmy Buffett Tickets at the Hollywood Bowl in Los Angeles/Hollywood, CA 2Health News:An Application to Evaluate Priorities Was Featured on NewsWatch Television on January 30, 2015 2Health News:Sex Sells! A Newly Minted Organic Bodycare Brand Courts Controversy at a Cost 2Health News:ZoomCare Announces 28-Location, On-Demand Neighborhood Health Campus 2Health News:ZoomCare Announces 28-Location, On-Demand Neighborhood Health Campus 3
... - Biopharmaceutical researchers have found a protein in blood ... cancer but which rarely shows up in the blood ... might help physicians decide whether smokers or others at ... lung imaging, say investigators, who presented their findings today ...
... In an 18-year-study on attention-deficit hyperactivity disorder (ADHD), ... stimulants is associated with improved long-term academic success ... are the first population-based data to show stimulant ... A related Mayo Clinic study reveals that compared ...
... for,International Development (USAID) today announced that Michael E. ... and,Humanitarian Assistance, is traveling to Zimbabwe, South Africa, ... his portfolio, Hess,oversees the USAID offices of Food ... and Governance., Hess,s regional trip will focus ...
... As predicted by opponents,to "assisted suicide," those seeking to ... slope,. Supporters of "assisted suicide,",including a few members of ... free counseling sessions -- via a new 1-800 number ... own lives. "This effort to put a clerical ...
... on the Importance of Physical Activity,for Adults and ... the nearly 100,million Americans who are overweight or ... weight loss and better health, which is the ... Physical Therapy,Association (APTA) announced today., According to ...
... generated by a 2002 study on the potential dangers ... the Stanford University School of Medicine found that only ... two years later. , Additionally, the women were able ... to hormone therapy just 40 percent of the time. ...
Cached Medicine News:Health News:Blood protein detects lung cancer, even at earliest stage 2Health News:Mayo Clinic study indicates medication for ADHD may help student outcomes 2Health News:Mayo Clinic study indicates medication for ADHD may help student outcomes 3Health News:USAID Assistant Administrator Hess Travels to Southern Africa 2Health News:This October, the American Physical Therapy Association's National Physical Therapy Month to Focus on Nation's Obesity Epidemic 2Health News:This October, the American Physical Therapy Association's National Physical Therapy Month to Focus on Nation's Obesity Epidemic 3Health News:This October, the American Physical Therapy Association's National Physical Therapy Month to Focus on Nation's Obesity Epidemic 4Health News:Less than one-third of women aware of landmark hormone therapy study, Stanford researcher finds 2Health News:Less than one-third of women aware of landmark hormone therapy study, Stanford researcher finds 3
... Tiburon™ surgical drapes from Cardinal Health will ... and draping in your facility. , ,Shrinking ... be carefully controlled at every turn without ... patient outcomes. Each decision must be evaluated ...
... Drape features less aggressive adhesive strip ... strip for easy removal, aggressive incise ... poly film, and product number identification. ... box of 5 or non-sterile in ...
... includes bed side and near patient testing ... This growth has posed unique problems for ... and quality responsibility to decentralized areas focused ... Compounding the problem is the reality of ...
... System includes genomic DNA Arrays, ... reagents. By utilizing Vysis' patented ... for multi-target assessment, the GenoSensor ... genomic targets in a single ...
Medicine Products: